Semaglutide and Tirzepatide API CDMO Market Size & Share 2026-2035

Semaglutide and Tirzepatide API CDMO Market Size

The semaglutide and tirzepatide API CDMO market was valued at USD 1.5 billion in 2025. The market is expected to grow from USD 1.9 billion in 2026 to USD 6.7 billion in 2035, at a CAGR of 15.2% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is witnessing robust growth, driven by the rapidly increasing outsourcing demand for peptide active pharmaceutical ingredient (API) development and manufacturing associated with semaglutide and tirzepatide therapies. The commercial success of GLP-1 receptor agonists such as Ozempic, Wegovy, and Rybelsus, along with dual GIP/GLP-1 receptor agonists including Mounjaro and Zepbound, has significantly increased the requirement for large-scale, high-quality peptide API manufacturing. This demand is further supported by the growing prevalence of obesity and type 2 diabetes worldwide.

According to the World Health Organization (WHO), approximately 890 million adults were living with obesity in 2022, while the International Diabetes Federation (IDF) estimated that 589 million adults aged 20–79 years were living with diabetes globally in 2024, with the number expected to reach 853 million by 2050. In response, innovator pharmaceutical companies are increasingly partnering with specialized contract development and manufacturing organizations (CDMOs) to expand manufacturing capacity, ensure supply continuity, accelerate commercialization, and overcome peptide production constraints.

Semaglutide and tirzepatide API CDMO comprises contract-based services for the development, scale-up, and commercial manufacturing of peptide active pharmaceutical ingredients used in semaglutide- and tirzepatide-based therapies. These highly complex peptide molecules require advanced manufacturing technologies, including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid peptide synthesis, high-purity purification processes, and comprehensive analytical characterization. CDMOs provide end-to-end services encompassing process development, analytical method development, technology transfer, clinical and commercial active pharmaceutical ingredient CDMO production, quality control, regulatory support, and supply chain management, enabling pharmaceutical and biotechnology companies to efficiently bring these therapies to market.

The competitive landscape is characterized by the presence of leading peptide manufacturing specialists such as Bachem, PolyPeptide Group, and Lonza, which continue to strengthen their market positions through investments in peptide synthesis capacity, purification technologies, manufacturing infrastructure, and long-term supply agreements with pharmaceutical companies. At the same time, Novo Nordisk and Eli Lilly are expanding their captive peptide API manufacturing capabilities to complement outsourced production, enhance supply-chain resilience, and meet the rapidly growing global demand for semaglutide- and tirzepatide-based products.

The semaglutide & tirzepatide API CDMO market has experienced exceptional growth over the past few years, increasing from USD 278.4 million in 2022 to USD 1 billion in 2024. This growth reflects substantial investments by both CDMOs and pharmaceutical manufacturers in expanding peptide synthesis capacity, enhancing purification capabilities, securing critical raw material supplies, and adopting advanced manufacturing technologies. Ongoing investments in new production facilities, peptide synthesis reactors, purification systems, and key raw materials such as Fmoc amino acids, resins, and coupling reagents are expected to further strengthen global manufacturing capacity and support the long-term growth of the market.

Semaglutide and Tirzepatide API CDMO Market Trends

• The semaglutide & tirzepatide API CDMO industry is witnessing significant investments in large-scale peptide manufacturing infrastructure as contract development and manufacturing organizations (CDMOs) expand production capacity to meet the rapidly increasing demand for semaglutide- and tirzepatide-based therapies for obesity and type 2 diabetes.
• Peptide API CDMOs are transitioning from conventional kilogram-scale manufacturing to multi-hundred-kilogram and metric-ton production capacities to support the commercial-scale supply requirements of GLP-1 and dual GIP/GLP-1 therapies.
• Manufacturers are increasingly adopting automation, digital process monitoring, advanced process analytical technologies (PAT), and data-driven manufacturing systems to improve process robustness, batch consistency, production yields, and overall operational efficiency.
• Significant investments are being directed toward purification, lyophilization, and downstream processing capabilities, as these operations have become key bottlenecks in scaling commercial production of semaglutide and tirzepatide APIs.
• Vertical integration is emerging as a strategic priority, with CDMOs strengthening control over critical raw materials, including peptide resins, Fmoc-protected amino acids, coupling reagents, and specialized intermediates, to enhance supply security and reduce dependence on external suppliers.
• Growing innovation in oral peptide formulations, next-generation GLP-1 receptor agonist, and combination peptide therapeutics is increasing the need for advanced peptide synthesis technologies, complex molecular modifications, and flexible commercial-scale manufacturing capabilities.
• Sustainability is becoming an increasingly important focus across the industry, driving investments in green peptide synthesis technologies, solvent recovery systems, waste minimization initiatives, and resource-efficient manufacturing processes to improve environmental performance while maintaining production efficiency

Semaglutide and Tirzepatide API CDMO Market Analysis

Based on API, the semaglutide & tirzepatide API CDMO market is divided into semaglutide and tirzepatide. The semaglutide segment has asserted its dominance in the market by securing a significant market share of 58.7% in 2025 stimulated by its broad commercial presence across multiple blockbuster brands, including Ozempic, Wegovy, and Rybelsus, as well as its established global manufacturing network and extensive patient adoption in diabetes and obesity management. The segment is expected to exceed USD 3.8 billion by 2035, growing at a CAGR of 14.8% during the forecast period.

• The strong commercial demand for semaglutide across multiple approved indications has significantly increased outsourcing requirements for peptide API development and large-scale commercial manufacturing. Its availability in both injectable and oral dosage forms has further expanded the addressable patient base, supporting sustained demand for API CDMO services.
• Continuous investments by peptide pharmaceutical CDMO in manufacturing capacity expansion, advanced peptide synthesis technologies, and purification infrastructure are strengthening the segment's growth. Rising prescription volumes, broader reimbursement coverage, and expanding global market penetration continue to reinforce semaglutide's leadership.
• The tirzepatide segment is anticipated to register a CAGR of 15.6% over the forecast period. Growth is primarily driven by the rapid commercial uptake of Mounjaro and Zepbound, increasing physician preference for dual GIP/GLP-1 receptor agonists, and rising demand for outsourced large-scale peptide API manufacturing. Geographic expansion, new therapeutic indications, and increasing outsourcing activities are expected to further accelerate segment growth.

Based on synthesis technology, the semaglutide & tirzepatide API CDMO market is divided into solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid technology, and other synthesis technologies. The solid-phase peptide synthesis (SPPS) segment dominated the market in 2025 with a revenue of USD 773.2 million.

• SPPS remains the preferred manufacturing technology for semaglutide and tirzepatide APIs due to its ability to efficiently synthesize complex peptide sequences while ensuring high product purity, consistency, and manufacturing reliability.
• The technology enables sequential amino acid coupling with simplified purification and process control, making it highly suitable for commercial-scale GLP-1 peptide API manufacturing. Its shorter development timelines, scalability, and operational flexibility further support its widespread adoption.
• The liquid-phase peptide synthesis (LPPS) segment is projected to grow at a CAGR of 15.3% during the forecast period, supported by its advantages in selected large-scale synthesis steps, improved scalability, and cost-efficient manufacturing for specific peptide production processes.
• The hybrid technology segment is expected to expand at a CAGR of 15.5%, driven by increasing adoption of integrated manufacturing approaches that combine the efficiency of SPPS with the scalability and cost advantages of LPPS for commercial peptide API production.

Based on service type, the semaglutide & tirzepatide API CDMO market is segmented into contract manufacturing, contract development, analytical & quality control services, regulatory & compliance support, and other services. The contract manufacturing segment dominated the market in 2025 with a market share of 62.1%.

• Contract manufacturing holds the largest market share owing to the substantial production volumes required to support the commercial supply of semaglutide- and tirzepatide-based therapies.
• The rapid growth of obesity and diabetes treatments has significantly increased demand for large-scale peptide synthesis, purification, and API production services, encouraging pharmaceutical companies to partner with specialized CDMOs.
• The contract development segment is expected to grow with a 15.8% CAGR during the analysis period, escalated by increasing demand for process optimization, route development, scale-up support, and technology transfer services as pharmaceutical companies advance next-generation obesity and metabolic disease therapies through clinical development.
• The analytical & quality control services segment is expected to grow with a 15.5% CAGR during the analysis period. The increasing complexity of peptide APIs and stringent regulatory requirements are driving demand for advanced analytical characterization, impurity profiling, stability testing, and quality assurance services to ensure product consistency and regulatory compliance.

Based on scale of operation, the semaglutide & tirzepatide API CDMO market is divided into clinical-scale manufacturing and commercial-scale manufacturing. The commercial-scale manufacturing segment dominated in 2025 and is anticipated to grow at a CAGR of 15% during the forecast period.

• The segment's leadership is driven by the rapidly increasing commercial demand for semaglutide- and tirzepatide-based therapies, expanding production requirements for approved products, and rising outsourcing of high-volume peptide API manufacturing.
• Commercial-scale manufacturing accounts for the largest share of the market due to the substantial API volumes required to support the global supply of approved obesity and diabetes treatments.
• Increasing worldwide adoption of GLP-1 therapies has accelerated investments in high-capacity peptide synthesis, purification, and commercial production infrastructure, making commercial manufacturing the largest revenue-generating segment within the market.
• The clinical-scale manufacturing segment is projected to grow at a CAGR of 15.6%, supported by increasing R&D activities involving next-generation GLP-1, dual GIP/GLP-1, and multi-receptor peptide therapeutics. Rising demand for clinical trial material, early-stage process development, and scale-up services is expected to drive segment growth.

Based on end use, semaglutide and tirzepatide API CDMO market is classified into healthcare pharmaceutical manufacturers, biotechnology companies, and research institutions & academic centers. The pharmaceutical manufacturers segment dominated the market with a revenue share of 74.3% in 2025 and is expected to reach USD 4.9 billion within the forecast period.   

• The segment's dominance is attributed to the commercialization of approved semaglutide- and tirzepatide-based therapies, increasing production requirements, and growing reliance on specialized peptide CDMOs for commercial API manufacturing.
• Expanding patient populations and rising global adoption of GLP-1-based therapies continue to drive demand for reliable, high-capacity peptide manufacturing and long-term outsourcing partnerships.
• The biotechnology companies segment is anticipated to register a CAGR of 15.5% during the forecast period, driven by increasing development of next-generation metabolic disease therapies, dual- and multi-receptor agonists, and innovative peptide drug candidates requiring outsourced development and manufacturing support.
• The research institutions & academic centers segment is expected to grow at a CAGR of 15.7%, supported by expanding research into novel peptide therapeutics, obesity and diabetes treatment strategies, and advanced peptide synthesis technologies, resulting in increasing demand for development, analytical, and pilot-scale manufacturing services.

North America Semaglutide and Tirzepatide API CDMO Market

The North America market dominated the semaglutide and tirzepatide API CDMO industry with a market share of 39.1% in 2025.

• The U.S. market was valued at USD 102.3 million and USD 205.1 million in 2022 and 2023, respectively. The market size reached USD 534.1 million in 2025, growing from USD 374.9 million in 2024.
• Growing efforts to localize pharmaceutical supply chains and reduce dependence on overseas manufacturing are accelerating investments in domestic peptide API production. For instance, CordenPharma's EURO 900 million investment announced in July 2024 to expand its peptide manufacturing platform highlights the increasing need for GLP-1 manufacturing capacity in the region.
• The strong presence of innovator pharmaceutical companies developing and commercializing semaglutide- and tirzepatide-based therapies continues to drive demand for outsourced peptide API development, process optimization, and commercial manufacturing services.
• In addition, pharmaceutical companies are increasingly entering long-term capacity reservation agreements with peptide CDMOs to secure manufacturing capacity amid persistent supply constraints for GLP-1 therapies.

Europe Semaglutide and Tirzepatide API CDMO Market

Europe semaglutide and tirzepatide API CDMO industry accounted for USD 424.3 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe remains a global hub for peptide API manufacturing, supported by the presence of leading peptide CDMOs that collectively account for a significant share of global peptide production capacity.
• Rising global demand for semaglutide and tirzepatide therapies is driving substantial investments in peptide synthesis and purification infrastructure. Companies such as Bachem continue to expand manufacturing facilities to meet the rapidly increasing demand for GLP-1 peptide APIs.
• The region also benefits from well-established GMP standards, advanced manufacturing expertise, a highly skilled workforce, and a mature regulatory environment, making Europe a preferred destination for peptide API development and commercial manufacturing.

Asia Pacific Semaglutide and Tirzepatide API CDMO Market

The Asia Pacific semaglutide and tirzepatide API CDMO industry is anticipated to grow at the highest CAGR of 15.6% during the analysis timeframe.

• Increasing pharmaceutical outsourcing activities and competitive manufacturing capabilities are positioning Asia Pacific as a major global production hub for semaglutide and tirzepatide peptide APIs.
• Rising demand for GLP-1 therapies has encouraged regional manufacturers to significantly expand production capacity. For example, WuXi TIDES has substantially increased its peptide manufacturing footprint, with total SPPS reactor capacity exceeding 30,000 liters to support commercial-scale peptide production.
• The region also benefits from a well-established supply chain for peptide raw materials, protected amino acids, intermediates, and specialized reagents, providing manufacturers with cost and operational advantages compared with many other regions.

Latin American Semaglutide and Tirzepatide API CDMO Market

The Latin America semaglutide and tirzepatide API CDMO industry is experiencing robust growth over the analysis timeframe.

• The increasing prevalence of obesity and type 2 diabetes is driving demand for advanced metabolic therapies, creating favorable opportunities for the adoption of semaglutide- and tirzepatide-based treatments across the region.
• Improving healthcare infrastructure, expanding access to innovative therapies, and growing awareness of obesity management are supporting the commercialization of GLP-1 peptide therapeutics.
• Brazil represents the largest market opportunity within Latin America due to its large pharmaceutical industry, expanding healthcare expenditure, and increasing demand for therapies targeting chronic metabolic diseases.

Middle East and Africa Semaglutide and Tirzepatide API CDMO Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• The rising prevalence of obesity, diabetes, and other metabolic disorders is increasing regional demand for innovative GLP-1 receptor agonist therapies.
• Government initiatives focused on healthcare modernization and improved access to advanced pharmaceutical products are supporting the adoption of specialty peptide therapeutics.
• The region remains heavily dependent on imported peptide APIs, creating significant opportunities for global peptide CDMOs to expand commercial partnerships, strengthen regional supply networks, and support the growing demand for semaglutide- and tirzepatide-based therapies.

Semaglutide and Tirzepatide API CDMO Market Share

The global semaglutide and tirzepatide API CDMO industry is highly concentrated, with a limited number of specialized peptide manufacturers competing to supply commercial-scale GLP-1 active pharmaceutical ingredients. Companies compete primarily on large-scale peptide synthesis capabilities, manufacturing capacity, regulatory compliance, supply reliability, and expertise in complex peptide production. Key participants include Bachem, PolyPeptide Group, CordenPharma, Lonza, and WuXi STA, which collectively account for an estimated 80% of the outsourced semaglutide and tirzepatide API CDMO market, owing to their established commercial manufacturing infrastructure and significant investments in GLP-1 peptide capacity expansion.

The competitive landscape continues to evolve as demand for obesity and diabetes therapies drives large-scale investments in peptide manufacturing assets. Market participants are expanding production capacity through new facilities, reactor installations, purification infrastructure, and strategic long-term manufacturing agreements with pharmaceutical companies. In addition, manufacturers are increasingly adopting advanced peptide synthesis technologies, automation platforms, and supply-chain integration strategies to improve scalability and address ongoing capacity constraints associated with semaglutide and tirzepatide production. The growing development of next-generation GLP-1, GIP, and multi-receptor metabolic therapies is further intensifying competition and creating opportunities for established peptide CDMOs to strengthen their market positions.

Semaglutide and Tirzepatide API CDMO Market Companies

Prominent players operating in the semaglutide and tirzepatide API CDMO industry are as mentioned below:

• AmbioPharm
• Asymchem Laboratories
• Bachem
• BCN Peptides
• Catalent
• CordenPharma
• CPC Scientific
• Lonza
• PolyPeptide Group
• WuXi STA (WuXi TIDES)
• CSBio
• Curia
• GenScript

• Bachem

Demonstrates strong leadership in the semaglutide and tirzepatide API CDMO market through its large-scale peptide manufacturing capabilities, extensive GLP-1-focused capacity expansions, and long-standing expertise in commercial peptide production. Its advanced solid-phase peptide synthesis (SPPS) infrastructure, global manufacturing footprint, and focus on high-volume obesity and diabetes peptide programs position it as a key supplier within the GLP-1 value chain.

• PolyPeptide Group

Operates as one of the world's largest specialized peptide API CDMOs, offering integrated development and commercial manufacturing services for complex therapeutic peptides. The company benefits from deep peptide synthesis expertise, multiple GMP manufacturing facilities, and expanding capabilities to support rising demand for GLP-1-based medicines, strengthening its position in the global semaglutide and tirzepatide supply ecosystem.

Semaglutide and Tirzepatide API CDMO Industry News

• In July 2024, CordenPharma announced a record investment of approximately €900 million to expand its peptide manufacturing platform across the U.S. and Europe. The expansion is aimed at increasing large-scale peptide production capacity to meet rapidly growing demand for GLP-1 therapies, supported by multiple long-term manufacturing contracts totaling approximately €3 billion.
• In December 2024, Novo Holdings completed its acquisition of Catalent, followed by Novo Nordisk's acquisition of three Catalent manufacturing facilities in the U.S., Belgium, and Italy. The transaction was undertaken to strengthen manufacturing capacity supporting semaglutide-based products and address growing global demand for GLP-1 therapies.

The semaglutide and tirzepatide API CDMO market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By API

• Semaglutide
• Tirzepatide

Market, By Synthesis Technology         

• Solid-phase peptide synthesis (SPPS) 
• Liquid-phase peptide synthesis (LPPS)
• Hybrid technology
• Other synthesis technologies

Market, By Service Type 

• Contract manufacturing
• Contract development
• Analytical & quality control services
• Regulatory & compliance support
• Other services

Market, By Scale of Operation   

• Clinical-scale manufacturing
• Commercial-scale manufacturing

Market, By End Use          

• Pharmaceutical manufacturers
• Biotechnology companies
• Research institutions & academic centers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE